Remy Robert

Summary

Affiliation: Monash University
Country: Australia

Publications

  1. ncbi request reprint Engineered antibody approaches for Alzheimer's disease immunotherapy
    Remy Robert
    Department of Immunology Clayton, Monash University, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Services, Clayton, Victoria 3800, Australia
    Arch Biochem Biophys 526:132-8. 2012
  2. pmc Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide
    Remy Robert
    CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia
    Mol Immunol 48:59-72. 2010
  3. doi request reprint Structural studies of the tethered N-terminus of the Alzheimer's disease amyloid-β peptide
    Rebecca M Nisbet
    Materials Science and Engineering and Preventative Health Flagship, CSIRO, Parkville, Victoria, 3052, Australia
    Proteins 81:1748-58. 2013
  4. doi request reprint Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers
    Remy Robert
    CSIRO Molecular and Health Technologies, University of Melbourne, Australia
    Protein Eng Des Sel 22:199-208. 2009
  5. pmc Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment
    Remy Robert
    CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia
    Protein Sci 19:299-308. 2010

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Engineered antibody approaches for Alzheimer's disease immunotherapy
    Remy Robert
    Department of Immunology Clayton, Monash University, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Services, Clayton, Victoria 3800, Australia
    Arch Biochem Biophys 526:132-8. 2012
    ..This review will address recent progress using these recombinant antibodies against Aβ, highlighting their advantages over conventional monoclonal antibodies and delivery methods...
  2. pmc Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide
    Remy Robert
    CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia
    Mol Immunol 48:59-72. 2010
    ..These findings may have important implications in designing more effective therapeutic antibodies against Aβ...
  3. doi request reprint Structural studies of the tethered N-terminus of the Alzheimer's disease amyloid-β peptide
    Rebecca M Nisbet
    Materials Science and Engineering and Preventative Health Flagship, CSIRO, Parkville, Victoria, 3052, Australia
    Proteins 81:1748-58. 2013
    ....
  4. doi request reprint Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers
    Remy Robert
    CSIRO Molecular and Health Technologies, University of Melbourne, Australia
    Protein Eng Des Sel 22:199-208. 2009
    ..Hence, these recombinant antibody fragments represent attractive candidates and safer formulations of passive immunotherapy for AD...
  5. pmc Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment
    Remy Robert
    CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia
    Protein Sci 19:299-308. 2010
    ..This humanized version retains a high affinity for the Abeta peptide and therefore is a potential candidate for passive immunotherapy of Alzheimer's disease...